| |
Department
of Pathology (HM, HK, SM, KA), Osaka University Graduate School of Medicine,
Suita; and Department of Internal Medicine (YA, MT), Kyoto Prefectural University
of Medicine, Kyoto, Japan |
| |
SUMMARY:
Etiological evidence, indicating the relationships between the onset
of malignant lymphoma and pre-existing chronic inflammation, has been
accumulated. For the autonomous growth of malignant tumor, genetic lesions,
such as chromosomal aberrations, amplification of oncogenes, and mutations
of genes involved in the cell cycle regulation, must be essential. However,
how the inflammation promotes the accumulation of genetic lesions and
induces the autonomous growth of lymphoid cells remains unclear. Reactive
oxygen species released by polymorphonuclear leukocytes and macrophages
are factors causing DNA damage in the foci of inflammation, and thus could
play a role in lymphomagenesis. The xanthine/xanthine oxidase (X/XOD)
system produces a mixture of hydrogen peroxide and superoxide anion extracellularly,
and thus serves as an in vitro source of reactive oxygen species. Cell
death of lymphoblastoid cell lines (LCLs) was induced with X/XOD treatment
in a dose-dependent manner. DNA fragmentation, which is the characteristic
feature of apoptosis, was observed in LCLs at 4-8 hours after X/XOD treatment.
Among cytokines such as interleukin-6(IL-6), IL-10, and interferon-g
, only pretreatment with IL-6 gave LCLs the resistance to X/XOD-induced
cell death in a dose-dependent manner. The proportion of apoptotic cells
in X/XOD-treated LCL culture was decreased with IL-6 pretreatment by quantification
with flow cytometric analysis. Treatment of LCLs with IL-6 for 48 hours
up-regulated bcl-2 mRNA expression. Furthermore, the LCLs repeatedly
treated with X/XOD and cultured with or without IL-6 showed many more
structural abnormalities of chromosomes than those without X/XOD treatment.
Colony forming efficiency of X/XOD-treated LCLs with IL-6 was significantly
higher than those without IL-6, and even relatively higher than LCLs without
X/XOD treatment. IL-6 could support the survival of non-neoplastic B cells
and accelerate the malignant transformation of B lineage cells in inflammatory
lesions.
|